Q1 2020 T2 Biosystems Inc Earnings Call
T2 Biosystems, Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that it has entered into a worldwide licensing agreement for a rapid COVID-19, novel coronavirus test developed by the Center of Discovery and Innovation at Hackensack Meridian Health, New Jersey’s largest and most comprehensive health network. The licensed coronavirus assay has been used by healthcare professionals within the Hackensack Meridian Health network, under the U.S. Food and Drug Administration’s Emergency Use Authorization guidance, to test and treat patients suspected of having coronavirus. Under terms of the agreement, T2 Biosystems will adapt the coronavirus test to run on its T2Dx® Instrument, the same instrument used for the FDA-cleared T2Bacteria® and T2Candida® Panels.
LEXINGTON, Mass., Feb. 12, 2020 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial.
Investors need to pay close attention to T2 Biosystems (TTOO) stock based on the movements in the options market lately.
LEXINGTON, Mass., April 21, 2020 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report.
Q4 2019 T2 Biosystems Inc Earnings Call
LEXINGTON, Mass., Feb. 24, 2020 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the.
T2 Biosystems, Inc. (NASDAQ:TTOO) came out with its annual results last week, and we wanted to see how the business is...
LEXINGTON, Mass., Feb. 19, 2020 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to.
T2 Biosystems, Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that it was awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country, covering its T2Dx® Instrument, as well as the T2Bacteria® and T2Candida® Panels, that detect sepsis-causing bacterial and fungal pathogens directly from whole blood. Vizient awards Innovative Technology contracts for technologies that demonstrate an ability to enhance clinical care and reduce the risk of harm to patients or providers, while simultaneously raising the standard of patient care and safety. “This multi-year agreement with the nation’s largest group purchasing organization demonstrates the value that T2 Biosystems’ unique technology confers to patients who are suspected of having sepsis,” said President and Chief Executive Officer John Sperzel.
T2 Biosystems, Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the Company’s participation in two conferences in February: Society of Critical Care Medicine’s (SCCM) 48th Critical Care Congress, and Medlab Middle East 19th Annual Laboratory Management and Medicine Conference.
T2 Biosystems, Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced unaudited, preliminary financial result estimates for the quarter ended March 31, 2020, and suspended full year 2020 financial and operational guidance due to uncertainties from the impact of the novel coronavirus (COVID-19) pandemic. The Company continues to leverage its technology and scientific expertise to aid in the COVID-19 response while prioritizing the health and safety of its employees and customers. T2 Biosystems recently announced a licensing agreement to support development of a rapid COVID-19 test, developed by the Center of Discovery and Innovation (CDI) at Hackensack Meridian Health, enabling a larger role in the pandemic response.
T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.
T2 Biosystems, Inc. (TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced it won the “Best New Technology Solution - Diagnostics" award for its T2Bacteria® Panel solution in the fourth annual MedTech Breakthrough Awards program. “We’re honored to be recognized by the MedTech Breakthrough Awards and grateful to the judges who recognize the importance of rapid identification of sepsis-causing pathogens in order to effectively and efficiently treat patients with bloodstream infections, which can lead to sepsis,” said John Sperzel, President and Chief Executive Officer of T2 Biosystems. The T2Bacteria Panel, which was FDA cleared in May 2018, can detect sepsis-causing bacterial pathogens directly from whole blood in three to five hours, without the need to wait for a blood culture, which typically takes days to provide results and is not as sensitive.
LEXINGTON, Mass., May 05, 2020 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord Blood Corp (NYSE: CO) * Thermogenesis Holdings Inc (NASDAQ: THMO)(reacted to its fourth-quarter earnings)Down In The Dumps * (Biotech Stocks Hitting 52-week lows on March 24) * Baudax Bio Inc (NASDAQ: BXRX) (reacted to announcement concerning common stock and warrant offerings) * Equillium Inc (NASDAQ: EQ) * IMMURON LTD/S ADR (NASDAQ: IMRN) * Milestone Pharmaceuticals Inc (NASDAQ: MIST) (reacted to an adverse clinical readout ) * Neovasc Inc (NASDAQ: NVCN) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * PLx Pharma Inc (NASDAQ: PLXP) * Salarius Pharmaceuticals Inc (NASDAQ: SLRX)(released its fourth-quarter results) * Viveve Medical Inc (NASDAQ: VIVE)Stocks In Focus T2 Biosystems Licenses COVID-19 Test, Preannounces Q1 Revenue Shortfall, Suspends Guidance T2 Biosystems Inc (NASDAQ: TTOO) said it has entered into a worldwide licensing agreement for a rapid COVID-19 test developed by Center of Discovery and Innovation at Hackensack Meridian Health.Under the agreement, T2 Biosystems will adapt the test to run on its T2Dx Instrument, the same instrument used for the FDA-cleared T2Bacteria and T2Candida Panels.Separately, the company preannounced a revenue shortfall for the first quarter, blaming the predicament on the COVID-19 pandemic, which has disrupted its commercial operations. The company also suspended its guidance for 2020.In after-hours trading, the stock jumped 109.16% to 82 cents.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.PerkinElmer's New Coronavirus Test Gets FDA Emergency Use Authorization PerkinElmer, Inc. (NYSE: PKI) said the FDA has issued Emergency Use Authorization for its new coronavirus RT-PCR test. This will allow clinical labs certified under Clinical Laboratory Improvement Amendments to immediately begin using the kit to detect SARS-CoV-2.In after-hours trading, the stock rose 3.01% to $76.55.Diffusion Pharma Announces Delay In Study of Lead Drug For Stroke Caused By Coronavirus Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) said it expects delays in enrollment in its ambulance-based PHAST-TSC Phase 2 trial in acute stroke due to coronavirus. The LA County Fire Department has suspended future training of first responders who had been scheduled to participate in the trial protocol, the company noted.Immuron Announces Strategic Actions to Tide Over COVID-19 Impact; CEO Steps Down Immuron announced measures to preserve capital, as it navigates through a tough environment amid the COVID-19 outbreak. As a first step, the company announced the resignation of Gary Jacob as CEO and member of the company's board. The company announced the appointment of Jerry Kanellos as CEO, with the move leading to day-to-day control of operations and executive strategy returning to Australia.The company also plans to do away with or significantly reduce external consultant costs and also establish a remuneration model for directors, which will use payment of board fees other than by monetary recompense. These are expected to trim cash operating expense by over $2 million, effective April.Immuron said it will also work toward increasing overall revenues to help mitigate an anticipated decrease in Travelan sales due to decreased travel by promoting Protectyn for gut benefits.Immutep's Immuno-chemotherapy Combo Produces Positive Results In Midstage Breast Cancer Trial Australian biotech IMMUTEP LTD/S ADR (NASDAQ: IMMP) announced data from the Phase 2b AIPAC study that evaluated its lead product candidate eftilagimod alpha in combination with paclitaxel, a taxane standard-of-care chemotherapy, in HER2-negative/HR+ metastatic breast cancer, which showed 63% of patients treated with the combo were progression-free at the 6-month landmark.This compared to 54% for patients who received paclitaxel plus placebo. The company also noted the secondary endpoint of overall response rate increased from 38.4% in the placebo group to 48.3% in the efti group.Allakos Reports Positive Results In Earlystage Study of Drug to Treat Mast Cell Gastrointestinal Disease Allakos Inc (NASDAQ: ALLK) announced positive results from a Phase 1 study that evaluated the safety and efficacy of antolimab in treating patients with mast cell gastrointestinal disease. Six months of treatment resulted in a 64% mean reduction in total symptom score-8, which measures abdominal pain, nausea, vomiting, early satiety, loss of appetite, abdominal cramping, bloating, and diarrhea. Antolimab was also found generally well tolerated, with no drug-related serious adverse events occurring during the study.Separately, the company also announced initiation of three clinical studies of antolimab - a Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis, a Phase 2/3 study in eosinophilic esophagitis, and a Phase 1 study of subcutaneously administered antolimab in healthy volunteers.The stock moved up 1.49% to $60 in after-hours trading.Exelixis' Partner Takeda Gets Regulatory Nod For Cabometyx In Japan For Kidney Cancer Exelixis, Inc. (NASDAQ: EXEL) said Takeda Pharmaceutical Co Ltd (NYSE: TAK), its partner responsible for the clinical development and commercialization of Cabometyx in Japan, received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market the drug as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma.In pre-market trading, Takeda shares were adding 0.79% to $14.01 and Exelixis shares were moving up 1.01% to $16.01.Earnings Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) reported a net loss of $2.86 per share for the fourth quarter of 2019 compared to a loss of $59.85 per share a year ago. Analysts estimated a loss of $1.49 per share for the quarter.In after-hours trading, the stock slipped 11.62% to 88 cents.Onconova Therapeutics Inc (NASDAQ: ONTX) reported full-year results that showed a loss of $1.49 per share for 2019 compared to a loss of $4.99 per share for 2018. Cash balance at the end of Feb. 2020 stood at $32.6 million. The company expects the cash and cash equivalents to be adequate to fund ongoing trials and operations into the third quarter of 2021.The company also said it has completed the planned enrollment of 360 patients in the INSPIRE trial in higher-risk myelodysplastic syndrome, or MDS, patients. It expects to report topline survival data in the second half of 2020.The stock advanced 14.48% to 42 cents in after-hours trading.On The Radar PDUFA Dates The FDA scheduled to announced its verdict on strong> Bristol-Myers Squibb Co (NYSE: BMY)'s NDA for ozanimod as a treatment option for patients with relapsing forms of multiple sclerosis.Earnings Viela Bio Inc (NASDAQ: VIE) (after the close)Biocept Inc (NASDAQ: BIOC) (after the close)OncoCyte Corp (NYSE: OCX) (after the close)HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the close)Eyenovia Inc (NASDAQ: EYEN) (after the close)Exagen Inc (NASDAQ: XGN) (after the close)See more from Benzinga * The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates * The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment * The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Companies In The News Are: TTWO, XERS, SPLK, NAVB
LEXINGTON, Mass., April 15, 2020 -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...
T2 Biosystems, Inc. (TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Chief Executive Officer (CEO), John Sperzel, has promoted Tony Pare to the newly created position of Chief Commercial Officer (CCO), effective immediately. Mr. Pare previously served as Vice President and General Manager – International at T2 Biosystems. “I am delighted to appoint Tony as our CCO and look forward to working with him to expand our commercial success,” said Mr. Sperzel.